Braidwell LP decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 38.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,500 shares of the medical research company’s stock after selling 49,500 shares during the quarter. Braidwell LP’s holdings in Natera were worth $21,580,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NTRA. Horizon Investments LLC increased its position in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares during the period. Parallel Advisors LLC boosted its position in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the period. First Horizon Corp boosted its position in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares during the period. Siemens Fonds Invest GmbH grew its stake in shares of Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH grew its stake in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after acquiring an additional 62 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.
Insider Transactions at Natera
In other news, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. This represents a 79.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares in the company, valued at approximately $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 62,348 shares of company stock valued at $15,870,496. Corporate insiders own 5.05% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Report on Natera
Natera Price Performance
Shares of Natera stock opened at $325.17 on Thursday. The firm has a market capitalization of $46.87 billion, a PE ratio of -239.09 and a beta of 1.54. The company’s fifty day moving average price is $289.96 and its two-hundred day moving average price is $236.14. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $343.18.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the firm earned ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
- Five stocks we like better than Natera
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
